Protecting the most vulnerable age group: a review of MenACWY-TT immunogenicity and safety in infants-Reference-Cited by-同舟云学术

Protecting the most vulnerable age group: a review of MenACWY-TT immunogenicity and safety in infants

Published:2020-04-02 Issue:4 Volume:19 Page:313-325
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Martinón-Torres Federico¹²^ORCID,Serra Lidia³,Safadi Marco Aurelio P.⁴^ORCID

Affiliation:

1. Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain

2. Genetics, Vaccines and Pediatrics Research Group, University of Santiago de Compostela, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain

3. Pfizer Vaccine Medical Development, Scientific & Clinical Affairs, Collegeville, PA, USA

4. Department of Pediatrics, Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil

Funder

Pfizer Inc

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2020.1745070

Reference77 articles.

1. Meningococcal disease: Clinical presentation and sequelae

2. The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines

3. Global epidemiology of invasive meningococcal disease

4. The Health Burden of Invasive Meningococcal Disease: A Systematic Review

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination;Expert Review of Vaccines;2024-06-07

2. Preventing invasive meningococcal disease in early infancy;Human Vaccines & Immunotherapeutics;2022-04-28

3. Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines;Human Vaccines & Immunotherapeutics;2021-02-19